NCT05735275

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A2102, In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies: A Phase I Open-Label, One-Arm, Multicenter Study.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 252 (estimated)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first in human, open-label, single-arm, multicenter dose escalation and expansion Phase 1 study of SHR-A2102 in patients with advanced or metastatic solid tumors. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A2102 and preliminary anti-tumor efficacy

Conditions

• Advanced Or Metastatic Solid Tumor Malignancies

Interventions

Type	Name	Description
DRUG	SHR-A2102	All participants receive SHR-A2102 alone.

Timeline

• Start date: 2023-03-03
• Primary completion: 2025-08-31
• Completion: 2025-08-31
• First posted: 2023-02-21
• Last updated: 2023-03-28

Locations

1 site across 1 country: China